Top

The Journal of Headache and Pain

Published in:

Open Access 01-12-2014 | Research article

Effect of genetic deletion and pharmacological antagonism of P2X7 receptors in a mouse animal model of migraine

Authors: Flóra Gölöncsér, Beáta Sperlágh

Published in: The Journal of Headache and Pain | Issue 1/2014

Abstract

Background

Purine receptors participate in peripheral and central sensitization and are associated with migraine headache. We investigated the role of P2X7 receptor (P2X7) in a nitroglycerin (NTG)-induced mouse model of migraine.

Methods

Intraperitoneal NTG injection (15 mg/kg) triggered thermal hyperalgesia in the hindpaws of wild-type C57BL/6J mice, followed by the induction of c-fos in upper cervical spinal cord and trigeminal nucleus caudalis. The effect of genetic deletion of P2X7 and the selective P2X7 antagonist Brilliant Blue G (BBG) were examined on hyperalgesia and c-fos induction.

Results

NTG decreased the paw withdrawal threshold in both wild-type and P2X7 knockout mice. Nevertheless, subacute BBG treatment (50 mg/kg/day i.p.) completely prevented the effect of NTG in wild-type, but not in knockout mice. Whereas P2X7 deficiency differentially affected the expression of c-fos, the average number of fos-immuno-reactive neurons in trigeminal nucleus caudalis, but not in upper cervical spinal cord was lower in BBG-treated wild-type mice after NTG treatment.

Conclusions

Our results show that P2X7 receptors might participate in the pathogenesis of migraine, although upregulation of other P2X receptors probably compensate for the loss of its action in knockout mice. The data also suggest the therapeutic potential of P2X7 antagonists for the treatment of migraine.

Available only for authorised users

Stovner L, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, Steiner T, Zwart JA: The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 2007, 27(3):193–210. 10.1111/j.1468-2982.2007.01288.xCrossRefPubMed

Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, Lipton RB: Global prevalence of chronic migraine: a systematic review. Cephalalgia 2010, 30(5):599–609.PubMed

Olesen J, Ashina M: Emerging migraine treatments and drug targets. Trends Pharmacol Sci 2011, 32(6):352–359. 10.1016/j.tips.2011.02.016CrossRefPubMed

Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH: An association between migraine and cutaneous allodynia. Ann Neurol 2000, 47(5):614–624. 10.1002/1531-8249(200005)47:5<614::AID-ANA9>3.0.CO;2-NCrossRefPubMed

Bigal ME, Ashina S, Burstein R, Reed ML, Buse D, Serrano D, Lipton RB, Group A: Prevalence and characteristics of allodynia in headache sufferers: a population study. Neurology 2008, 70(17):1525–1533. 10.1212/01.wnl.0000310645.31020.b1PubMedCentralCrossRefPubMed

Gupta S, Villalon CM: The relevance of preclinical research models for the development of antimigraine drugs: focus on 5-HT(1B/1D) and CGRP receptors. Pharmacol Ther 2010, 128(1):170–190. 10.1016/j.pharmthera.2010.06.005CrossRefPubMed

Iversen HK, Olesen J, Tfelt-Hansen P: Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain 1989, 38(1):17–24. 10.1016/0304-3959(89)90067-5CrossRefPubMed

Sicuteri F, Del Bene E, Poggioni M, Bonazzi A: Unmasking latent dysnociception in healthy subjects. Headache 1987, 27(4):180–185. 10.1111/j.1526-4610.1987.hed2704180.xCrossRefPubMed

Sances G, Tassorelli C, Pucci E, Ghiotto N, Sandrini G, Nappi G: Reliability of the nitroglycerin provocative test in the diagnosis of neurovascular headaches. Cephalalgia 2004, 24(2):110–119. 10.1111/j.1468-2982.2004.00639.xCrossRefPubMed

10.

Bahra A, Matharu MS, Buchel C, Frackowiak RS, Goadsby PJ: Brainstem activation specific to migraine headache. Lancet 2001, 357(9261):1016–1017. 10.1016/S0140-6736(00)04250-1CrossRefPubMed

11.

Tvedskov JF, Thomsen LL, Iversen HK, Gibson A, Wiliams P, Olesen J: The prophylactic effect of valproate on glyceryltrinitrate induced migraine. Cephalalgia 2004, 24(7):576–585. 10.1111/j.1468-2982.2003.00720.xCrossRefPubMed

12.

Tvedskov JF, Thomsen LL, Thomsen LL, Iversen HK, Williams P, Gibson A, Jenkins K, Peck R, Olesen J: The effect of propranolol on glyceryltrinitrate-induced headache and arterial response. Cephalalgia 2004, 24(12):1076–1087. 10.1111/j.1468-2982.2004.00796.xCrossRefPubMed

13.

de Tommaso M, Libro G, Guido M, Difruscolo O, Losito L, Sardaro M, Cerbo R: Nitroglycerin induces migraine headache and central sensitization phenomena in patients with migraine without aura: a study of laser evoked potentials. Neurosci Lett 2004, 363(3):272–275. 10.1016/j.neulet.2004.04.029CrossRefPubMed

14.

Bates EA, Nikai T, Brennan KC, Fu YH, Charles AC, Basbaum AI, Ptacek LJ, Ahn AH: Sumatriptan alleviates nitroglycerin-induced mechanical and thermal allodynia in mice. Cephalalgia 2010, 30(2):170–178.PubMed

15.

Tassorelli C, Joseph SA: Systemic nitroglycerin induces Fos immunoreactivity in brainstem and forebrain structures of the rat. Brain Res 1995, 682(1–2):167–181.CrossRefPubMed

16.

Lambert GA, Donaldson C, Boers PM, Zagami AS: Activation of trigeminovascular neurons by glyceryl trinitrate. Brain Res 2000, 887(1):203–210. 10.1016/S0006-8993(00)02919-XCrossRefPubMed

17.

Sixt ML, Messlinger K, Fischer MJ: Calcitonin gene-related peptide receptor antagonist olcegepant acts in the spinal trigeminal nucleus. Brain 2009, 132(Pt 11):3134–3141.CrossRefPubMed

18.

Burnstock G: Pathophysiology of migraine: a new hypothesis. Lancet 1981, 1(8235):1397–1399.CrossRefPubMed

19.

Ambalavanar R, Moritani M, Dessem D: Trigeminal P2X3 receptor expression differs from dorsal root ganglion and is modulated by deep tissue inflammation. Pain 2005, 117(3):280–291. 10.1016/j.pain.2005.06.029CrossRefPubMed

20.

Fabbretti E, D’Arco M, Fabbro A, Simonetti M, Nistri A, Giniatullin R: Delayed upregulation of ATP P2X3 receptors of trigeminal sensory neurons by calcitonin gene-related peptide. J Neurosci 2006, 26(23):6163–6171. 10.1523/JNEUROSCI.0647-06.2006CrossRefPubMed

21.

Fumagalli M, Ceruti S, Verderio C, Abbracchio M: ATP as a neurotransmitter of pain in migraine: a functional role for P2Y receptors in primary cultures from mouse trigeminal sensory ganglia. Purinergic signalling 2006, 2(1):120–121.

22.

D’Arco M, Giniatullin R, Simonetti M, Fabbro A, Nair A, Nistri A, Fabbretti E: Neutralization of nerve growth factor induces plasticity of ATP-sensitive P2X3 receptors of nociceptive trigeminal ganglion neurons. J Neurosci 2007, 27(31):8190–8201. 10.1523/JNEUROSCI.0713-07.2007CrossRefPubMed

23.

Simonetti M, Giniatullin R, Fabbretti E: Mechanisms mediating the enhanced gene transcription of P2X3 receptor by calcitonin gene-related peptide in trigeminal sensory neurons. J Biol Chem 2008, 283(27):18743–18752. 10.1074/jbc.M800296200CrossRefPubMed

24.

Ceruti S, Villa G, Fumagalli M, Colombo L, Magni G, Zanardelli M, Fabbretti E, Verderio C, van den Maagdenberg AM, Nistri A, Abbracchio MP: Calcitonin gene-related peptide-mediated enhancement of purinergic neuron/glia communication by the algogenic factor bradykinin in mouse trigeminal ganglia from wild-type and R192Q Cav2.1 Knock-in mice: implications for basic mechanisms of migraine pain. J Neurosci 2011, 31(10):3638–3649. 10.1523/JNEUROSCI.6440-10.2011CrossRefPubMed

25.

Heinrich A, Ando RD, Turi G, Rozsa B, Sperlagh B: K + depolarization evokes ATP, adenosine and glutamate release from glia in rat hippocampus: a microelectrode biosensor study. Br J Pharmacol 2012, 167(5):1003–1020. 10.1111/j.1476-5381.2012.01932.xPubMedCentralCrossRefPubMed

26.

Schock SC, Munyao N, Yakubchyk Y, Sabourin LA, Hakim AM, Ventureyra EC, Thompson CS: Cortical spreading depression releases ATP into the extracellular space and purinergic receptor activation contributes to the induction of ischemic tolerance. Brain Res 2007, 1168: 129–138.CrossRefPubMed

27.

D’Amico M, Samengo I, Navarra P, Taglialatela M, Martire M: AMPA- and P2X7-receptor-mediated facilitation of [3H]D-aspartate release from nerve terminals isolated from the rat caudal brainstem. Neurochem Int 2010, 57(6):623–628. 10.1016/j.neuint.2010.07.009CrossRefPubMed

28.

Able SL, Fish RL, Bye H, Booth L, Logan YR, Nathaniel C, Hayter P, Katugampola SD: Receptor localization, native tissue binding and ex vivo occupancy for centrally penetrant P2X7 antagonists in the rat. Br J Pharmacol 2011, 162(2):405–414. 10.1111/j.1476-5381.2010.01025.xPubMedCentralCrossRefPubMed

29.

Magni G, Ceruti S: P2Y purinergic receptors: new targets for analgesic and antimigraine drugs. Biochem Pharmacol 2013, 85(4):466–477. 10.1016/j.bcp.2012.10.027CrossRefPubMed

30.

Chessell IP, Hatcher JP, Bountra C, Michel AD, Hughes JP, Green P, Egerton J, Murfin M, Richardson J, Peck WL, Grahames CB, Casula MA, Yiangou Y, Birch R, Anand P, Buell GN: Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain 2005, 114(3):386–396. 10.1016/j.pain.2005.01.002CrossRefPubMed

31.

Ando RD, Sperlagh B: The role of glutamate release mediated by extrasynaptic P2X7 receptors in animal models of neuropathic pain. Brain Res Bull 2013, 93: 80–85.CrossRefPubMed

32.

Ando RD, Mehesz B, Gyires K, Illes P, Sperlagh B: A comparative analysis of the activity of ligands acting at P2X and P2Y receptor subtypes in models of neuropathic, acute and inflammatory pain. Br J Pharmacol 2010, 159(5):1106–1117. 10.1111/j.1476-5381.2009.00596.xPubMedCentralCrossRefPubMed

33.

Honore P, Donnelly-Roberts D, Namovic MT, Hsieh G, Zhu CZ, Mikusa JP, Hernandez G, Zhong C, Gauvin DM, Chandran P, Harris R, Medrano AP, Carroll W, Marsh K, Sullivan JP, Faltynek CR, Jarvis MF: A-740003 [N-(1-{[(cyanoimino)(5-quinolinylamino) methyl] amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl) acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat. J Pharmacol Exp Ther 2006, 319(3):1376–1385. 10.1124/jpet.106.111559CrossRefPubMed

34.

Chu YX, Zhang Y, Zhang YQ, Zhao ZQ: Involvement of microglial P2X7 receptors and downstream signaling pathways in long-term potentiation of spinal nociceptive responses. Brain Behav Immun 2010, 24(7):1176–1189. 10.1016/j.bbi.2010.06.001CrossRefPubMed

35.

McGaraughty S, Chu KL, Namovic MT, Donnelly-Roberts DL, Harris RR, Zhang XF, Shieh CC, Wismer CT, Zhu CZ, Gauvin DM, Fabiyi AC, Honore P, Gregg RJ, Kort ME, Nelson DW, Carroll WA, Marsh K, Faltynek CR, Jarvis MF: P2X7-related modulation of pathological nociception in rats. Neuroscience 2007, 146(4):1817–1828. 10.1016/j.neuroscience.2007.03.035CrossRefPubMed

36.

Sorge RE, Trang T, Dorfman R, Smith SB, Beggs S, Ritchie J, Austin JS, Zaykin DV, Vander Meulen H, Costigan M, Herbert TA, Yarkoni-Abitbul M, Tichauer D, Livneh J, Gershon E, Zheng M, Tan K, John SL, Slade GD, Jordan J, Woolf CJ, Peltz G, Maixner W, Diatchenko L, Seltzer Z, Salter MW, Mogil JS: Genetically determined P2X7 receptor pore formation regulates variability in chronic pain sensitivity. Nat Med 2012, 18(4):595–599. 10.1038/nm.2710PubMedCentralCrossRefPubMed

37.

Solle M, Labasi J, Perregaux DG, Stam E, Petrushova N, Koller BH, Griffiths RJ, Gabel CA: Altered cytokine production in mice lacking P2X(7) receptors. J Biol Chem 2001, 276(1):125–132. 10.1074/jbc.M006781200CrossRefPubMed

38.

Diaz-Hernandez M, Diez-Zaera M, Sanchez-Nogueiro J, Gomez-Villafuertes R, Canals JM, Alberch J, Miras-Portugal MT, Lucas JJ: Altered P2X7-receptor level and function in mouse models of Huntington’s disease and therapeutic efficacy of antagonist administration. FASEB J 2009, 23(6):1893–1906. 10.1096/fj.08-122275CrossRefPubMed

39.

Csolle C, Ando RD, Kittel A, Goloncser F, Baranyi M, Soproni K, Zelena D, Haller J, Nemeth T, Mocsai A, Sperlagh B: The absence of P2X7 receptors (P2rx7) on non-haematopoietic cells leads to selective alteration in mood-related behaviour with dysregulated gene expression and stress reactivity in mice. Int J Neuropsychopharmacol 2013, 16(1):213–233. 10.1017/S1461145711001933PubMedCentralCrossRefPubMed

40.

Sokolowska M, Bednarski M, Kwiecien I, Filipek B, Wlodek L: Bioactivation of nitroglycerin to nitric oxide (NO) and S-nitrosothiols in the rat liver and evaluation of the coexisting hypotensive effect. Fundam Clin Pharmacol 2004, 18(4):449–456. 10.1111/j.1472-8206.2004.00265.xCrossRefPubMed

41.

Almasi R, Petho G, Bolcskei K, Szolcsanyi J: Effect of resiniferatoxin on the noxious heat threshold temperature in the rat: a novel heat allodynia model sensitive to analgesics. Br J Pharmacol 2003, 139(1):49–58. 10.1038/sj.bjp.0705234PubMedCentralCrossRefPubMed

42.

Hracsko Z, Baranyi M, Csolle C, Goloncser F, Madarasz E, Kittel A, Sperlagh B: Lack of neuroprotection in the absence of P2X7 receptors in toxin-induced animal models of Parkinson’s disease. Mol Neurodegener 2011, 6: 28. 10.1186/1750-1326-6-28PubMedCentralCrossRefPubMed

43.

Jo S, Bean BP: Inhibition of neuronal voltage-gated sodium channels by brilliant blue G. Mol Pharmacol 2011, 80(2):247–257. 10.1124/mol.110.070276PubMedCentralCrossRefPubMed

44.

Diaz-Hernandez JI, Gomez-Villafuertes R, Leon-Otegui M, Hontecillas-Prieto L, Del Puerto A, Trejo JL, Lucas JJ, Garrido JJ, Gualix J, Miras-Portugal MT, Diaz-Hernandez M: In vivo P2X7 inhibition reduces amyloid plaques in Alzheimer’s disease through GSK3beta and secretases. Neurobiol Aging 2012, 33(8):1816–1828. 10.1016/j.neurobiolaging.2011.09.040CrossRefPubMed

45.

Jiang LH, Mackenzie AB, North RA, Surprenant A: Brilliant Blue G selectively blocks ATP-gated rat P2X(7) receptors. Mol Pharmacol 2000, 58(1):82–88.PubMed

46.

Collier HO, James GW, Schneider C: Antagonism by aspirin and fenamates of bronchoconstriction and nociception induced by adenosine-5′-triphosphate. Nature 1966, 212(5060):411–412. 10.1038/212411a0CrossRefPubMed

47.

Sperlagh B, Vizi ES, Wirkner K, Illes P: P2X(7) receptors in the nervous system. Prog Neurobiol 2006, 78(6):327–346. 10.1016/j.pneurobio.2006.03.007CrossRefPubMed

48.

Zhang X, Chen Y, Wang C, Huang LY: Neuronal somatic ATP release triggers neuron-satellite glial cell communication in dorsal root ganglia. Proc Natl Acad Sci U S A 2007, 104(23):9864–9869. 10.1073/pnas.0611048104PubMedCentralCrossRefPubMed

49.

Teixeira JM, Oliveira MC, Nociti FH Jr, Clemente-Napimoga JT, Pelegrini-da-Silva A, Parada CA, Tambeli CH: Involvement of temporomandibular joint P2X3 and P2X2/3 receptors in carrageenan-induced inflammatory hyperalgesia in rats. Eur J Pharmacol 2010, 645(1–3):79–85.CrossRefPubMed

50.

Nair A, Simonetti M, Birsa N, Ferrari MD, van den Maagdenberg AM, Giniatullin R, Nistri A, Fabbretti E: Familial hemiplegic migraine Ca(v)2.1 channel mutation R192Q enhances ATP-gated P2X3 receptor activity of mouse sensory ganglion neurons mediating trigeminal pain. Mol Pain 2010, 6: 48. 10.1186/1744-8069-6-48PubMedCentralCrossRefPubMed

51.

Akerman S, Holland PR, Goadsby PJ: Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci 2011, 12(10):570–584. 10.1038/nrn3057CrossRefPubMed

52.

Csolle C, Sperlagh B: Peripheral origin of IL-1beta production in the rodent hippocampus under in vivo systemic bacterial lipopolysaccharide (LPS) challenge and its regulation by P2X(7) receptors. J Neuroimmunol 2010, 219(1–2):38–46.CrossRefPubMed

53.

Remy M, Thaler S, Schumann RG, May CA, Fiedorowicz M, Schuettauf F, Gruterich M, Priglinger SG, Nentwich MM, Kampik A, Haritoglou C: An in vivo evaluation of Brilliant Blue G in animals and humans. Br J Ophthalmol 2008, 92(8):1142–1147. 10.1136/bjo.2008.138164CrossRefPubMed

54.

Wong HE, Qi W, Choi HM, Fernandez EJ, Kwon I: A safe, blood–brain barrier permeable triphenylmethane dye inhibits amyloid-beta neurotoxicity by generating nontoxic aggregates. ACS Chem Neurosci 2011, 2(11):645–657. 10.1021/cn200056gPubMedCentralCrossRefPubMed

Title: Effect of genetic deletion and pharmacological antagonism of P2X7 receptors in a mouse animal model of migraine
Authors: Flóra Gölöncsér
Beáta Sperlágh
Publication date: 01-12-2014
Publisher: Springer Milan
Published in: The Journal of Headache and Pain / Issue 1/2014
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI: https://doi.org/10.1186/1129-2377-15-24

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Effect of genetic deletion and pharmacological antagonism of P2X7 receptors in a mouse animal model of migraine

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Ophthalmoplegia starting with a headache circumscribed in a line-shaped area: a subtype of ophthalmoplegic migraine?

Cuneus and fusiform cortices thickness is reduced in trigeminal neuralgia

The origin of nausea in migraine–A PET study

Refractory chronic migraine: a Consensus Statement on clinical definition from the European Headache Federation

Risk factors for migraine and tension-type headache in 11 year old children

Expression of 5-HT3 receptors and TTX resistant sodium channels (NaV1.8) on muscle nerve fibers in pain-free humans and patients with chronic myofascial temporomandibular disorders